Fisher Asset Management LLC Increases Holdings in Stryker Co. (NYSE:SYK)

Fisher Asset Management LLC raised its holdings in shares of Stryker Co. (NYSE:SYK) by 2.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,042,317 shares of the medical technology company’s stock after purchasing an additional 103,326 shares during the period. Fisher Asset Management LLC’s holdings in Stryker were worth $1,210,512,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. Keybank National Association OH grew its stake in Stryker by 3.5% in the third quarter. Keybank National Association OH now owns 27,823 shares of the medical technology company’s stock worth $7,603,000 after purchasing an additional 952 shares during the period. Carnegie Capital Asset Management LLC increased its position in shares of Stryker by 0.5% during the fourth quarter. Carnegie Capital Asset Management LLC now owns 96,241 shares of the medical technology company’s stock valued at $28,820,000 after acquiring an additional 497 shares in the last quarter. CoreCap Advisors LLC grew its position in Stryker by 3.9% in the 4th quarter. CoreCap Advisors LLC now owns 5,030 shares of the medical technology company’s stock worth $1,506,000 after purchasing an additional 191 shares during the period. Consolidated Planning Corp bought a new position in Stryker in the fourth quarter valued at about $205,000. Finally, Meritage Portfolio Management purchased a new position in Stryker in the fourth quarter worth about $569,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Down 1.0 %

SYK stock traded down $3.12 during trading on Thursday, reaching $325.00. 672,113 shares of the company traded hands, compared to its average volume of 1,310,056. Stryker Co. has a 12 month low of $249.98 and a 12 month high of $361.41. The company has a market capitalization of $123.65 billion, a price-to-earnings ratio of 37.46, a price-to-earnings-growth ratio of 2.71 and a beta of 0.91. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.97 and a current ratio of 1.58. The business has a 50 day simple moving average of $348.05 and a 200 day simple moving average of $316.78.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, April 30th. The medical technology company reported $2.50 EPS for the quarter, beating analysts’ consensus estimates of $2.36 by $0.14. The company had revenue of $5.24 billion during the quarter, compared to analysts’ expectations of $5.10 billion. Stryker had a return on equity of 23.44% and a net margin of 16.03%. The firm’s revenue was up 9.7% compared to the same quarter last year. During the same period last year, the business posted $2.14 earnings per share. On average, equities research analysts anticipate that Stryker Co. will post 11.86 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th were paid a dividend of $0.80 per share. The ex-dividend date was Wednesday, March 27th. This represents a $3.20 annualized dividend and a dividend yield of 0.98%. Stryker’s payout ratio is currently 36.53%.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Stifel Nicolaus raised their price objective on shares of Stryker from $350.00 to $375.00 and gave the stock a “buy” rating in a report on Wednesday. Robert W. Baird lifted their price target on shares of Stryker from $367.00 to $378.00 and gave the company an “outperform” rating in a report on Wednesday. Roth Mkm increased their price target on Stryker from $348.00 to $405.00 and gave the stock a “buy” rating in a research note on Wednesday. Evercore ISI upped their target price on shares of Stryker from $340.00 to $370.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Finally, Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and lifted their target price for the stock from $315.00 to $360.00 in a report on Wednesday, January 31st. Four analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and an average price target of $357.05.

Insider Activity at Stryker

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of Stryker stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the sale, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now owns 3,675 shares in the company, valued at $1,317,414. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Allan C. Golston sold 3,273 shares of the company’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the completion of the transaction, the director now directly owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The disclosure for this sale can be found here. Insiders have sold a total of 212,109 shares of company stock valued at $72,845,768 in the last ninety days. Company insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.